Navigation Links
Palatin Technologies Receives $1.1 Million From Sale of New Jersey State Tax Credits
Date:1/17/2012

CRANBURY, N.J., Jan. 17, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today it has received net proceeds of approximately $1.1 million of non-dilutive funding through the New Jersey Economic Development Authority's tax credit transfer program.  Palatin Technologies sold both New Jersey net operating losses and research and development tax credits to unrelated corporations.

Last year, Palatin Technologies received approximately $637,000 under this program.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets Eighth Annual Equity Conference
2. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
3. Alan Dunton, M.D., Joins Board of Directors of Palatin Technologies, Inc.
4. Palatin Technologies, Inc. March 31, 2011 Quarter Results; Teleconference and Webcast to be Held on May 16, 2011
5. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
6. Palatin Technologies, Inc. Closes $23 Million Public Offering
7. Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex
8. Palatin Technologies Receives Non-Compliance Letter from NYSE Amex
9. Palatin Technologies to Present at 9th Annual BIO Investor Forum
10. Palatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference
11. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):